Experimental Alzheimer’s Drug May Slow Decline, But Safety Concerns Linger
WEDNESDAY, Nov. 30, 2022 (HealthDay News) — The experimental Alzheimer’s drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain. In the eagerly awaited trial findings, published Tuesday in the New EnglandContinue Reading